Why the study?
Does type 2 diabetes worsen clinical outcomes and angiographic/IVUS features in patients undergoing PCI with sirolimus-eluting stents for de-novo lesions?
Does type 2 diabetes worsen clinical outcomes and angiographic/IVUS features in patients undergoing PCI with sirolimus-eluting stents for de-novo lesions?
While sirolimus-eluting stents neutralize the excess risk of intimal hyperplasia in diabetic patients, these patients still face higher rates of adverse clinical outcomes compared to nondiabetics.
Diabetes predicts higher post-PCI MACE despite sirolimus-eluting stents; supports trials of adjunctive strategies in this population.
OBJECTIVES: This study aimed to evaluate the impact of angiographic and intravascular ultrasound (IVUS) features on clinical outcome in nondiabetic and type 2 diabetic patients after percutaneous coronary intervention (PCI) with sirolimus-eluting stent (SES) implantation. METHODS: Repeat coronary angiography with IVUS imaging was performed after SES-based PCI for de-novo lesions in 128 diabetic and 327 nondiabetic patients (189 lesions and 504 lesions, respectively). The rate of major adverse cardiac events including cardiac death, non fatal myocardial infarction (MI), and target lesion revascularization during clinical follow-up was recorded. RESULTS: In-stent and in-segment late loss, intimal hyperplasia volume, and percentage volumetric obstruction were similar, but stented external elastic membrane cross-sectional area and reference/stented segment ratio were lower in diabetic than in nondiabetic patients. Incomplete stent apposition (ISA) was less frequent, but occurrence of new coronary lesions was higher in diabetic than in nondiabetic patients. Despite similar target lesion revascularization, cumulative survival rates freedom from composite cardiac death and nonfatal MI or major adverse cardiac events were reduced in diabetic patients. Cox proportional hazards model identified diabetes, left ventricular ejection fraction, minimal stent CSA, maximal ISA area, atherosclerotic progression and lesion length as independent predictors of non fatal MI or mortality at follow-up. CONCLUSION: In diabetic patients, PCI with SES implantation neutralizes the excess risk of intimal hyperplasia and decreases occurrence of ISA, but could not modify the propensity of increased adverse clinical outcomes at follow-up.
No takes yet. Share an insight, caveat, or question.
Du et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: